Compare
Eloxx Pharmaceuticals, Inc. vs Vaxart, Inc. vs Amgen Inc vs Repligen Corp
| Latest fiscal year | Eloxx Pharmaceuticals, Inc. ELOX | Vaxart, Inc. VXRT | Amgen Inc AMGN | Repligen Corp RGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $237.26M | $36.75B | $738.26M |
| Revenue growth (YoY) | -100.0% | +726.7% | +10.0% | +16.4% |
| Gross margin | n/a | n/a | 67.2% (computed) | 52.3% (computed) |
| Operating margin | n/a | 7.6% | 24.7% | 7.5% |
| Net margin | n/a | 6.9% | 21.0% | 6.6% |
| Net income | -$6.00M | $16.33M | $7.71B | $48.89M |
| EPS (Diluted) | -$0.49 | $0.07 | $14.23 | $0.86 |
| Operating cash flow | -$6.33M | $7.71M | $9.96B | $117.42M |
| Free cash flow | n/a | $7.57M | $8.10B | $93.90M |
| Cash & equivalents | $4.79M | n/a | $9.13B | $566.02M |
| Total assets | $5.27M | $186.08M | $90.59B | $2.95B |
| Total liabilities | $17.18M | $98.28M | n/a | $843.57M |
| Shareholders' equity | -$11.91M | $87.80M | $8.66B | $2.11B |
| Return on year-end equity | n/a | 18.6% | 89.1% | 2.3% |
| Shares outstanding | 4.79M | 240.49M | 538.80M | 56.33M |
Revenue, most recent five fiscal years
| Fiscal year | Eloxx Pharmaceuticals, Inc. | Vaxart, Inc. | Amgen Inc | Repligen Corp |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $237.26M Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $738.26M Ended 2025-12-31 |
| 1 year earlier | $6.36M Ended 2024-12-31 | $28.70M Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $634.44M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $7.38M Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $632.36M Ended 2023-12-31 |
| 3 years earlier | n/a | $107.0K Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $801.54M Ended 2022-12-31 |
| 4 years earlier | n/a | $892.0K Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $670.53M Ended 2021-12-31 |